Arvinas vs IDEAYA Biosciences
ARVN and IDYA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARVN and IDYA compare
IDEAYA Biosciences is the larger company, worth 5.9 times as much as Arvinas ($2.6B against $446M).
Arvinas keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −74.8% at IDEAYA Biosciences.
IDEAYA Biosciences scores higher on the StockData Score (10 against 8 for Arvinas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARVN | IDYA |
|---|---|---|
| Size and price | ||
| Market cap | $446M | $2.6B |
| Share price | $6.82 | $27.40 |
| Change, 1 year | −35.5% | −14.7% |
| Change, 5 years | −91.3% | 15.1% |
| Beta (5Y) | 2.00 | 1.11 |
| Employees | 246 | 145 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.6× | – |
| P/S | 1.4× (better) | 11.3× |
| P/B | 0.8× (better) | 2.2× |
| FCF yield | −46.8% | −4.3% (better) |
| Fair value | – | $29.50 |
| Margin of safety | – | 7.1% |
| Growth | ||
| Revenue growth (TTM) | −15.0% | – |
| Revenue growth, 5Y average | 58.9% | 62.1% (better) |
| Profitability | ||
| Operating margin | −5.7% (better) | −92.7% |
| Net margin | 2.9% (better) | −74.8% |
| FCF margin | −65.9% | −48.6% (better) |
| Return on equity | 1.6% (better) | −16.2% |
| Return on invested capital | – | −51.9% |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 7.91 | 10.45 (better) |
| Altman Z-score | 0.65 | 13.65 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.0% | 106% |
| Held by insiders | 7.8% | 0.83% |
| Insider net buying, 12 months | −$1.2M | $281K (better) |
| Short interest, % of float | 9.5% | 8.6% |
Go deeper
- ARVN stock overview
- ARVN income statement
- ARVN valuation and score
- IDYA stock overview
- IDYA income statement
- IDYA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.